Kevin Kalinsky, MD, on Clinical Practice Pearls: Updated Results on Endocrine Therapy and Chemotherapy for HR-Positive HER2-Negative Breast Cancer

Posted: Tuesday, January 25, 2022

Kevin Kalinsky, MD, of the Winship Cancer Institute at Emory University, discusses recent phase III findings on the use of chemotherapy and endocrine therapy and how the data may be applied to customize treatment for patients with hormone receptor–positive, HER2-negative breast cancer.